To the Editor: Dr Regine and colleagues1 attempted to determine whether the addition of gemcitabine to adjuvant fluorouracil chemoradiation improved survival for patients with resected pancreatic adenocarcinoma. They hypothesized that patients in the control group would have a median survival of 18 months and gemcitabine would increase that to 27 months or more. Patients were stratified by nodal status, tumor diameter, and surgical margin status.
Vikram B. Survival for Patients With Pancreatic Cancer After Addition of Gemcitabine to Fluorouracil Chemoradiation. JAMA. 2008;299(24):2852–2853. doi:10.1001/jama.299.24.2852-b
Customize your JAMA Network experience by selecting one or more topics from the list below.